<DOC>
	<DOCNO>NCT01032200</DOCNO>
	<brief_summary>RATIONALE : Armodafinil may help relieve fatigue improve quality life patient cancer receive radiation therapy brain . PURPOSE : This clinical trial study well armodafinil work treat fatigue cause radiation therapy patient primary brain tumor .</brief_summary>
	<brief_title>Armodafinil Treating Fatigue Caused By Radiation Therapy Patients With Primary Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To estimate study accrual , adherence , retention , participation patient primary brain tumor undergoing partial- whole-brain radiotherapy randomize receive armodafinil placebo . - To estimate variability fatigue , quality life , neurocognitive function patient . Secondary - To obtain preliminary estimate effect armodafinil fatigue measure fatigue subscale FACIT-F Brief Fatigue Inventory . - To estimate rate toxicity adverse event associate armodafinil . - To obtain preliminary estimate effect armodafinil sleepiness measure Epworth Sleep Scale ; overall quality life brain-specific quality life measure FACT-G brain subscale ; cognitive function measure comprehensive Wake Forest Cognitive Function Battery . OUTLINE : This multicenter study . Patients stratify accord therapy ( radiotherapy alone vs radiotherapy chemotherapy ) Karnofsky performance status ( 60-80 % vs 90-100 % ) . Patients randomize 1 2 arm . - Arm I : Patients receive oral armodafinil daily begin later fifth fraction brain radiotherapy continue 9-11 week absence unacceptable toxicity . - Arm II : Patients receive oral placebo daily begin later fifth fraction brain radiotherapy continue 9-11 week absence unacceptable toxicity . Patients complete questionnaire assess fatigue , quality life , neurocognitive function baseline periodically study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>Inclusion Criteria Histologically confirm primary brain tumor , include follow : Glioblastoma multiforme Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic mixed oligoastrocytoma Lowgrade glioma Meningioma Ependymoma Other primary brain tumor histology Planning undergo externalbeam cranial radiotherapy ( partial wholebrain radiotherapy ) meeting follow criterion : Total dose ≥ 4,500 cGy Total number fraction ≥ 25 fraction Dose per fraction ≥ 150 cGy PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Hemoglobin ≥ 10.0 g/dL ( erythropoietin transfusion allow symptomatically anemic patient hemoglobin &lt; 10 g/dL ) Creatinine ≤ 2 mg/dL Total bilirubin ≤ 2 time upper limit normal ( ULN ) SGOT SGPT ≤ 3 time ULN Not pregnant nursing Negative pregnancy test Sexually active woman childbearing potential must use reliable method birth control It recommend patient use nonhormonal contraceptive , addition place hormonal contraceptive , one month follow treatment armodafinil Prior malignancy allow No baseline headache ( i.e. , headache occur week baseline assessment ) grade 4 severity ( define severe disable headache , require analgesic , interfere prevent function activity daily live ) No concurrent uncontrolled illness may cause fatigue ; interfere drug absorption , distribution , metabolism , excretion ; limit compliance study requirement include , limited , follow : Ongoing active infection Chronic renal insufficiency Psychiatric illness ( psychosis , psychotic disorder , history suicide attempt , actively suicidal ) Extreme social situation ( e.g. , transportation issue would preclude study compliance ) Patients history cardiac issue ( symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia ) use armodafinil may cause chest pain , palpitation , dyspnea , transient ischemic Twave change ECG No history allergic reaction attribute modafinil armodafinil No anticipate plan excessive consumption coffee , tea , and/or caffeinecontaining beverage average &gt; 600 mg caffeine/day ( i.e. , approximately 6 cup coffee/day , 12 cup hot tea/day , 12 can cola/day ) PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior fractionate externalbeam cranial radiotherapy More 30 day since prior monoamine oxidate inhibitor investigational drug More 2 week since prior concurrent modafinil ( Provigil ) , donepezil ( Aricept ) , memantine hydrochloride ( Namenda ) , methylphenidate ( Ritalin ) , dextroamphetamineamphetamine ( Adderall ) , ginkgo biloba , cognitive functionenhancing drug At least 4 week since prior concurrent interstitial intracavitary chemotherapy and/or radiotherapy stereotactic radiosurgery ( i.e. , Gamma Knife , Linac , Cyberknife ) No concurrent erythropoietin , transfusion , iron therapy ( unless patient symptomatically anemic hemoglobin &lt; 10 g/dL ) Concurrent chemotherapy allow Concurrent hormonal therapy malignancy allow No concurrent nonhormonal therapy ( e.g. , Herceptin target agent ) , cytotoxic chemotherapy No concurrent clopidogrel bisulfate ( Plavix )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>fatigue</keyword>
	<keyword>cognitive/functional effect</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
	<keyword>adult subependymal giant cell astrocytoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult ependymoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adult anaplastic meningioma</keyword>
	<keyword>adult grade I meningioma</keyword>
	<keyword>adult grade II meningioma</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult papillary meningioma</keyword>
	<keyword>adult brain stem glioma</keyword>
</DOC>